Navigation Links
PRA Early Phase Leaders to Speak at Bioanalysis Forum
Date:6/21/2011

RALEIGH, N.C., June 21, 2011 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that two bioanalytical experts from our Early Development Services (EDS) group will speak at the European Bioanalysis Forum being held 21-22 June 2011 in Brussels, Belgium.

On day one of the meeting, Dr. Nico van de Merbel, Scientific Director of PRA's bioanalytical laboratory in The Netherlands, will host a session titled, "The Use of Internal Standards for Macromolecule Quantification by LC-MS: Lessons Learned from Small Molecule Assays." The presentation will compare possible approaches for using internal standards in LC-MS based macromolecule assays. It also will explore each approach's analytical performance and practical utility.

Dr. Martin Nemansky, who also serves as Scientific Director of our Netherlands lab, will present, "Sense and Nonsense of Quantitative Analysis of Biologics - or Why Should We Care?" on day two. The discussion will examine critical questions concerning novel biologics, new batches of biologics and the development of biosimilars. The discussion will also evaluate a variety of assay methods for their functionality within the development and registration process of large molecule drugs.

Dr. van de Merbel's field of expertise is the bioanalytical application of chromatographic methods (HPLC, LC-MS/MS) for small molecules. At PRA, he oversees the development and validation of chromatographic methods for small molecules in biological samples. Dr. Nemansky has specialized expertise in the application of biochemical and immunological methods for the bioanalysis of large molecules. This field includes method development, validation and quantitative determination of large molecule drugs, anti-drug antibodies, biomarkers and endogenous compounds.

PRA EDS is an international group helping pharmaceutical and biotechnology clients in our Phase I development programs. Through our harmonized clinical and laboratory facilities in The Netherlands, the United States and Central and Eastern Europe, PRA offers over 275 beds for patient and subject studies worldwide. Our global teams can meet the needs of any Phase I study design required in the industry today.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency.  PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge.  Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs.  But at PRA, we are looking to the future, not the past.  Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit www.praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System
2. Kendle Appoints Pierre Geoffroy, MD, CM, MSc, FCFP Vice President, Early Stage
3. MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breast Cancer Patients
4. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
5. Abstracts Reporting EarlyCDT™-Lung Demonstrate Diagnostic and Economic Benefits of Immuno-biomarkers in Early Detection of Solid Tumor Lung Cancers
6. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
7. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
8. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
9. Drug-Related Poisoning The Cause For Nearly 700,000 Emergency Department Visits a Year, According to New Research
10. Six Health Plans Pay $1.5 Million in Incentives to Create Medical Homes for Nearly Half a Million Hudson Valley Residents
11. Zimmer Announces Early Clinical Success of Zimmer® MotionLoc™ Screw Implantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Nearly 30 million people ... from the epidemic of diabetes. 1 However, nearly ... elevated glucose levels (hyperglycemia) and significant glucose variability. 2 ... complications, including cardiovascular events. If left untreated, hyperglycemia can ... eye disease or blindness. 3 As ...
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... , Dec. 6, 2016  Blueprint Medicines Corporation ... and developing targeted kinase medicines for patients with genomically ... underwritten public offering of $125,000,000 million in shares of ... grant the underwriters a 30-day option to purchase up ... its common stock in connection with the public offering. ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):